経口生物製剤とバイオシミラー医薬品の世界市場レポート 2025年

経口生物製剤とバイオシミラー医薬品市場規模は、今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は15.1％で、151億1,000万米ドルに成長します。予測期間の成長は、標的治療、予防医療への注目の高まり、ヘルスケア支出の増加、高齢化などに起因しています。予測期間の主な動向には、経口投与技術の進歩、経口投与生物製剤、バイオシミラーの革新、患者中心の医療などがあります。

関節炎、喘息、がんなどの慢性疾患の流行は、経口生物製剤およびバイオシミラー市場の成長を促進すると予想されます。長時間労働、身体活動の制限、不健康な食生活などの要因が慢性疾患の増加に寄与しており、その治療に生物製剤が利用されるケースが増えています。これらの医薬品は、免疫系ががん細胞と闘うきっかけを作り、がん細胞の排除を助ける。国連は、2030年までに世界の死因の約70％が慢性疾患に起因し、これらの疾患による世界の負担は約60％に達すると予測しています。その結果、慢性疾患の急増が生物製剤とバイオシミラーの需要を煽り、経口生物製剤とバイオシミラー医薬品市場の成長に拍車をかけると予想されます。

個別化医療に対する需要の高まりは、経口生物製剤およびバイオシミラー医薬品市場の成長を促進します。個別化医療とは、医療上の決定や薬物療法を個々の患者に合わせて調整することです。このアプローチは、経口生物学的製剤とバイオシミラーの開発と利用と一致し、副作用を最小限に抑えながら治療効果を最適化し、試行錯誤の方法を減らすことで、奏効率の向上と生存期間の延長につながります。2022年10月のSTATによるレポートでは、75,000を超える遺伝子検査製品と300を超える個別化医薬品が示されており、個別化医療に対する需要の高まりが腫瘍分子診断市場の成長を牽引していることが強調されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界経口生物製剤とバイオシミラー医薬品 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の経口生物製剤とバイオシミラー医薬品市場：成長率分析
• 世界の経口生物製剤とバイオシミラー医薬品市場の実績：規模と成長, 2019-2024
• 世界の経口生物製剤とバイオシミラー医薬品市場の予測：規模と成長, 2024-2029, 2034F
• 世界経口生物製剤とバイオシミラー医薬品総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の経口生物製剤とバイオシミラー医薬品市場：セラピー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• リンパ球モジュレーター
• インターロイキン阻害剤
• 腫瘍壊死因子α阻害剤
• 世界の経口生物製剤とバイオシミラー医薬品市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 喘息
• クローン病
• がん
• 関節炎
• 糖尿病
• 多発性骨髄腫
• 腸炎
• 多発性硬化症
• 肉腫
• 乾癬など
• 世界の経口生物製剤とバイオシミラー医薬品市場分子の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ワクチン
• タンパク質とペプチド
• モノクローナル抗体
• その他の分子タイプ
• 世界の経口生物製剤とバイオシミラー医薬品市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の経口生物製剤とバイオシミラー医薬品市場リンパ球調節薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• フィンゴリモド
• オクレリズマブ
• ナタリズマブ
• 世界の経口生物製剤とバイオシミラー医薬品市場インターロイキン阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ウステキヌマブ
• セクキヌマブ
• グセルクマブ
• 世界の経口生物製剤とバイオシミラー医薬品市場腫瘍壊死因子α阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アダリムマブ
• セルトリズマブペゴル
• ゴリムマブ

第7章 地域別・国別分析

• 世界の経口生物製剤とバイオシミラー医薬品市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の経口生物製剤とバイオシミラー医薬品市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 経口生物製剤とバイオシミラー医薬品市場：競合情勢
• 経口生物製剤とバイオシミラー医薬品市場：企業プロファイル
  • Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • Rani Therapeutics Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Biocon Limited
• Oramed Pharmaceuticals Inc.
• BiosanaPharma
• Entera Bio Ltd.
• Allergan plc
• Emisphere Technologies Inc.
• Enteris BioPharma Inc.
• Chiasma Inc.
• Allena Pharmaceuticals Inc.
• Gelgen Corporation
• Ganlee Corporation
• 3SBio Inc.
• Innovent Biologics Inc.
• Retractable Technologies Inc.
• Changchun High & New Technology Industries（Group）Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 経口生物製剤とバイオシミラー医薬品市場2029：新たな機会を提供する国
• 経口生物製剤とバイオシミラー医薬品市場2029：新たな機会を提供するセグメント
• 経口生物製剤とバイオシミラー医薬品市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A biosimilar is a medication designed to closely resemble a biologic drug both structurally and functionally. Biologic drugs are treatments produced using biological systems like yeast, bacteria, or animal cells. A biological product is deemed 'biosimilar' if it closely matches an FDA-approved reference product with no clinically discernible differences.

Within therapy types, there are oral biologics and biosimilars categorized as lymphocyte modulators, interleukin inhibitors, and tumor necrosis factor-alpha inhibitors. Interleukin inhibitors are immunosuppressive drugs that hinder interleukins' functionality. Interleukins are a group of cytokines generated by lymphocytes, monocytes, macrophages, and various other cells, crucial in regulating the immune system. These drugs treat various conditions such as asthma, Crohn's disease, carcinoma, arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, sarcoma, psoriasis, and others. They are available in forms like vaccines, proteins, peptides, monoclonal antibodies, distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The oral biologics and biosimilar market research report is one of a series of new reports from The Business Research Company that provides oral biologics and biosimilar market statistics, including oral biologics and biosimilar industry global market size, regional shares, competitors with an oral biologics and biosimilar market share, detailed oral biologics and biosimilar market segments, market trends and opportunities, and any further data you may need to thrive in the oral biologics and biosimilar industry. This oral biologics and biosimilar market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oral biologics & biosimilar drugs market size has grown rapidly in recent years. It will grow from $7.19 billion in 2024 to $8.6 billion in 2025 at a compound annual growth rate (CAGR) of 19.6%. The growth in the historic period can be attributed to rising prevalence of chronic diseases, growing awareness of oral biologics, increasing patent expirations, rising demand for biosimilars.

The oral biologics & biosimilar drugs market size is expected to see rapid growth in the next few years. It will grow to $15.11 billion in 2029 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to targeted therapy, increasing focus on preventive medicine, rising healthcare spending, aging population. Major trends in the forecast period include advancements in oral delivery technology, orally administered biologics, biosimilar innovation, and patient-centric care.

The prevalence of chronic conditions like arthritis, asthma, and cancer is anticipated to drive growth in the oral biologics and biosimilar market. Factors such as extended work hours, limited physical activity, and unhealthy dietary habits contribute to the rise in chronic diseases, and biologics are increasingly utilized for their treatment. These medications trigger the immune system to combat cancer cells, aiding in their elimination. The United Nations projects that by 2030, about 70% of global deaths will be attributed to chronic diseases, with the global burden of these conditions expected to reach approximately 60%. Consequently, the surge in chronic diseases is expected to fuel demand for biologics and biosimilars, spurring growth in the oral biologics and biosimilar drugs market.

The escalating demand for personalized medicine is set to propel growth in the oral biologics and biosimilar drugs market. Personalized medicine involves tailoring medical decisions and drug therapies to individual patients. This approach aligns with the development and utilization of oral biologics and biosimilars, optimizing treatment efficacy while minimizing side effects and reducing trial-and-error methods, leading to higher response rates and extended survival. Reports by STAT in October 2022 indicated over 75,000 genetic testing products and 300 personalized medicines, underscoring the increasing demand for personalized medicine driving growth in the oncology molecular diagnostics market.

A noteworthy trend in the oral biologics and biosimilar market is the creation of new insulin biosimilars. Key market players are investing in developing biosimilar versions of insulin, fostering competition among different biosimilar manufacturers. For instance, in April 2023, Eli Lilly and Company introduced Rezvoglar (insulin glargine-aglr), a biosimilar of insulin glargine used for improving glycemic control in adults, children, and infants with type 1 diabetes, as well as adults with type 2 diabetes.

Major companies in the oral biologics and biosimilar markets are concentrating on innovative products, such as incretin triagonists, to improve patient outcomes, enhance drug efficacy, and provide alternatives to injectable therapies. Incretin triagonists are medications that activate three hormone receptors-GLP-1, GIP, and glucagon-helping to regulate blood sugar, appetite, and metabolism. For example, in October 2024, Rani Therapeutics Holdings Inc., a biotechnology company based in the US, announced new preclinical pharmacokinetic data that supports the transenteric delivery of a GLP-1 incretin triagonist. Their RaniPill, an oral capsule designed to deliver biologics that typically require injections, successfully administered an incretin triagonist targeting the GLP-1, GIP, and glucagon receptors, which are critical in obesity treatment. The RaniPill showed effectiveness comparable to subcutaneous injections, providing a needle-free alternative with high bioavailability and flexible dosing, positioning it as a promising option for obesity drug candidates.

Major companies operating in the oral biologics & biosimilar drugs market include Novartis International AG, Rani Therapeutics Holdings Inc., Eli Lilly and Company, AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals Inc., BiosanaPharma, Entera Bio Ltd., Allergan plc, Emisphere Technologies Inc., Enteris BioPharma Inc., Chiasma Inc., Allena Pharmaceuticals Inc., Gelgen Corporation, 3SBio Inc., Innovent Biologics Inc., Changchun High & New Technology Industries (Group) Inc., Dong Bao Pharmaceutical Co. Ltd., CP Guojian Pharmaceutical Co. Ltd., GlaxoSmithKline PLC, Concord Biotech Limited, Aurobindo Pharma Limited, H. Lundbeck A/S, Sanofi S.A., F. Hoffmann-La Roche Ltd., Allergan Pharmaceuticals International Limited, Hikma Pharmaceuticals PLC, Mylan N.V., Pfizer Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd.

North America was the largest region in the oral biologics and biosimilar drugs market in 2024. The Middle East is expected to be the fastest growing region in the oral biologics & biosimilar drugs market report during the forecast period. The regions covered in the oral biologics & biosimilar drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the oral biologics & biosimilar drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The oral biologics and biosimilar market consist of sales of therapeutic proteins, cystic fibrosis, somatic cells, and allergenics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oral Biologics & Biosimilar Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oral biologics & biosimilar drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oral biologics & biosimilar drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oral biologics & biosimilar drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapy: Lymphocyte Modulators; Interleukin Inhibitors; Tumor Necrosis Factor-Alpha Inhibitors
• 2) By Disease: Asthma; Crohn's Disease; Carcinoma; Arthritis; Diabetes; Multiple Myeloma; Enterocolitis; Multiple Sclerosis; Sarcoma; Psoriasis and Others
• 3) By Molecule Type: Vaccines; Proteins & Peptides; Monoclonal Antibodies; Other Molecule Types
• 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• Subsegments:
• 1) By Lymphocyte Modulators: Fingolimod; Ocrelizumab; Natalizumab
• 2) By Interleukin Inhibitors: Ustekinumab; Secukinumab; Guselkumab
• 3) By Tumor Necrosis Factor-Alpha Inhibitors: Adalimumab; Certolizumab Pegol; Golimumab
• Companies Mentioned: Novartis International AG; Rani Therapeutics Holdings Inc.; Eli Lilly and Company; AstraZeneca plc; Novo Nordisk A/S
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oral Biologics & Biosimilar Drugs Market Characteristics

3. Oral Biologics & Biosimilar Drugs Market Trends And Strategies

4. Oral Biologics & Biosimilar Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Oral Biologics & Biosimilar Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Oral Biologics & Biosimilar Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Oral Biologics & Biosimilar Drugs Market Growth Rate Analysis
• 5.4. Global Oral Biologics & Biosimilar Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Oral Biologics & Biosimilar Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Oral Biologics & Biosimilar Drugs Total Addressable Market (TAM)

6. Oral Biologics & Biosimilar Drugs Market Segmentation

• 6.1. Global Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lymphocyte Modulators
• Interleukin Inhibitors
• Tumor Necrosis Factor-Alpha Inhibitors
• 6.2. Global Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Asthma
• Crohn's Disease
• Carcinoma
• Arthritis
• Diabetes
• Multiple Myeloma
• Enterocolitis
• Multiple Sclerosis
• Sarcoma
• Psoriasis and Others
• 6.3. Global Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vaccines
• Proteins & Peptides
• Monoclonal Antibodies
• Other Molecule Types
• 6.4. Global Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Oral Biologics & Biosimilar Drugs Market, Sub-Segmentation Of Lymphocyte Modulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fingolimod
• Ocrelizumab
• Natalizumab
• 6.6. Global Oral Biologics & Biosimilar Drugs Market, Sub-Segmentation Of Interleukin Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ustekinumab
• Secukinumab
• Guselkumab
• 6.7. Global Oral Biologics & Biosimilar Drugs Market, Sub-Segmentation Of Tumor Necrosis Factor-Alpha Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adalimumab
• Certolizumab Pegol
• Golimumab

7. Oral Biologics & Biosimilar Drugs Market Regional And Country Analysis

• 7.1. Global Oral Biologics & Biosimilar Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Oral Biologics & Biosimilar Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oral Biologics & Biosimilar Drugs Market

• 8.1. Asia-Pacific Oral Biologics & Biosimilar Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oral Biologics & Biosimilar Drugs Market

• 9.1. China Oral Biologics & Biosimilar Drugs Market Overview
• 9.2. China Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oral Biologics & Biosimilar Drugs Market

• 10.1. India Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oral Biologics & Biosimilar Drugs Market

• 11.1. Japan Oral Biologics & Biosimilar Drugs Market Overview
• 11.2. Japan Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oral Biologics & Biosimilar Drugs Market

• 12.1. Australia Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oral Biologics & Biosimilar Drugs Market

• 13.1. Indonesia Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oral Biologics & Biosimilar Drugs Market

• 14.1. South Korea Oral Biologics & Biosimilar Drugs Market Overview
• 14.2. South Korea Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oral Biologics & Biosimilar Drugs Market

• 15.1. Western Europe Oral Biologics & Biosimilar Drugs Market Overview
• 15.2. Western Europe Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oral Biologics & Biosimilar Drugs Market

• 16.1. UK Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oral Biologics & Biosimilar Drugs Market

• 17.1. Germany Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oral Biologics & Biosimilar Drugs Market

• 18.1. France Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oral Biologics & Biosimilar Drugs Market

• 19.1. Italy Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oral Biologics & Biosimilar Drugs Market

• 20.1. Spain Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oral Biologics & Biosimilar Drugs Market

• 21.1. Eastern Europe Oral Biologics & Biosimilar Drugs Market Overview
• 21.2. Eastern Europe Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oral Biologics & Biosimilar Drugs Market

• 22.1. Russia Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oral Biologics & Biosimilar Drugs Market

• 23.1. North America Oral Biologics & Biosimilar Drugs Market Overview
• 23.2. North America Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oral Biologics & Biosimilar Drugs Market

• 24.1. USA Oral Biologics & Biosimilar Drugs Market Overview
• 24.2. USA Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oral Biologics & Biosimilar Drugs Market

• 25.1. Canada Oral Biologics & Biosimilar Drugs Market Overview
• 25.2. Canada Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oral Biologics & Biosimilar Drugs Market

• 26.1. South America Oral Biologics & Biosimilar Drugs Market Overview
• 26.2. South America Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oral Biologics & Biosimilar Drugs Market

• 27.1. Brazil Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oral Biologics & Biosimilar Drugs Market

• 28.1. Middle East Oral Biologics & Biosimilar Drugs Market Overview
• 28.2. Middle East Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oral Biologics & Biosimilar Drugs Market

• 29.1. Africa Oral Biologics & Biosimilar Drugs Market Overview
• 29.2. Africa Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oral Biologics & Biosimilar Drugs Market Competitive Landscape And Company Profiles

• 30.1. Oral Biologics & Biosimilar Drugs Market Competitive Landscape
• 30.2. Oral Biologics & Biosimilar Drugs Market Company Profiles
  • 30.2.1. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Rani Therapeutics Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis

31. Oral Biologics & Biosimilar Drugs Market Other Major And Innovative Companies

• 31.1. Biocon Limited
• 31.2. Oramed Pharmaceuticals Inc.
• 31.3. BiosanaPharma
• 31.4. Entera Bio Ltd.
• 31.5. Allergan plc
• 31.6. Emisphere Technologies Inc.
• 31.7. Enteris BioPharma Inc.
• 31.8. Chiasma Inc.
• 31.9. Allena Pharmaceuticals Inc.
• 31.10. Gelgen Corporation
• 31.11. Ganlee Corporation
• 31.12. 3SBio Inc.
• 31.13. Innovent Biologics Inc.
• 31.14. Retractable Technologies Inc.
• 31.15. Changchun High & New Technology Industries (Group) Inc.

32. Global Oral Biologics & Biosimilar Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oral Biologics & Biosimilar Drugs Market

34. Recent Developments In The Oral Biologics & Biosimilar Drugs Market

35. Oral Biologics & Biosimilar Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Oral Biologics & Biosimilar Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Oral Biologics & Biosimilar Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Oral Biologics & Biosimilar Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer